Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy
Soujanya Sunkaraneni,1 Julie A Passarell,2 Elizabeth A Ludwig,2 Jill Fiedler-Kelly,2 Janet K Pitner,1 Todd A Grinnell,1 David Blum1 1Sunovion Pharmaceuticals Inc., Marlborough, MA, USA; 2Cognigen Corporation (a SimulationsPlus company), Buffalo, NY, USA Purpose: Eslicarbazepine acetate (ESL) is a on...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2017
|
| Subjects: | |
| Online Access: | https://doaj.org/article/cc916b7b6de44a4b81813f80ae1e3b03 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|